Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles D Blanke

Showing results (11-20 of 152) with videos related to

Pageof 16
Sort By:
British Journal of Hospital Medicine (London, England : 2005)|February 28, 2024
Safeguards for medical aid in dyingCharles D Blanke
Diabetes/Metabolism Research and Reviews|May 27, 2020
In response: Diabetes is a risk factor for the progression and prognosis of COVID-19Charles D Blanke
Cancer Chemotherapy and Pharmacology|December 1, 2010
Metastatic gastrointestinal stromal tumorsFrancine Aubin, Charles D Blanke
Seminars in Oncology|February 24, 2005
Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust?Rachel Sanborn, Charles D Blanke
Gastroenterology|March 23, 2011
Gastrointestinal stromal tumors: disease and treatment updateMaria Y Ho, Charles D Blanke
JAMA Oncology|April 1, 2016
Duration of Adjuvant Therapy for Patients With Gastrointestinal Stromal Tumors: Where Is Goldilocks When We Need Her?Charles D Blanke, Ronald P DeMatteo
Cancer Investigation|June 11, 2005
State-of-the art therapy for gastrointestinal stromal tumorsCharles D Blanke, Christopher L Corless
Progress in Experimental Tumor Research|June 11, 2003
Chemotherapy with cyclooxygenase-2 inhibitors in the treatment of malignant disease: pre-clinical rationale and preliminary results of clinical trialsCharles D Blanke, Jaime L Masferrer
JAMA Oncology|July 24, 2015
Chemotherapy Near the End of Life: First--and Third and Fourth (Line)--Do No HarmCharles D Blanke, Erik K Fromme
Clinical Advances in Hematology & Oncology : H&O|September 17, 2005
Gastrointestinal stromal tumors and the evolution of targeted therapyRachel E Sanborn, Charles D Blanke
Pageof 16

Showing results (11-20 of 152) with videos related to

Sort By:
Pageof 16
British Journal of Hospital Medicine (London, England : 2005)|February 28, 2024
Safeguards for medical aid in dyingCharles D Blanke
Diabetes/Metabolism Research and Reviews|May 27, 2020
In response: Diabetes is a risk factor for the progression and prognosis of COVID-19Charles D Blanke
Cancer Chemotherapy and Pharmacology|December 1, 2010
Metastatic gastrointestinal stromal tumorsFrancine Aubin, Charles D Blanke
Seminars in Oncology|February 24, 2005
Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust?Rachel Sanborn, Charles D Blanke
Gastroenterology|March 23, 2011
Gastrointestinal stromal tumors: disease and treatment updateMaria Y Ho, Charles D Blanke
JAMA Oncology|April 1, 2016
Duration of Adjuvant Therapy for Patients With Gastrointestinal Stromal Tumors: Where Is Goldilocks When We Need Her?Charles D Blanke, Ronald P DeMatteo
Cancer Investigation|June 11, 2005
State-of-the art therapy for gastrointestinal stromal tumorsCharles D Blanke, Christopher L Corless
Progress in Experimental Tumor Research|June 11, 2003
Chemotherapy with cyclooxygenase-2 inhibitors in the treatment of malignant disease: pre-clinical rationale and preliminary results of clinical trialsCharles D Blanke, Jaime L Masferrer
JAMA Oncology|July 24, 2015
Chemotherapy Near the End of Life: First--and Third and Fourth (Line)--Do No HarmCharles D Blanke, Erik K Fromme
Clinical Advances in Hematology & Oncology : H&O|September 17, 2005
Gastrointestinal stromal tumors and the evolution of targeted therapyRachel E Sanborn, Charles D Blanke
Pageof 16